# **Result Update**

# **Gulf Oil Lubricants**

Refer to important disclosures at the end of this report

# Covid-19 disruption hit March-end sales; volumes bottomed in April

CMP: Rs 629 as of (June 18, 2020)

TP: Rs 870 (▼)
12 months

Rating: BUY (■)

**Upside: 38.3 %** 



# ASIAMONEY

We appreciate your support in the Asiamoney Brokers Poll 2020

- Gulf Oil Lubricants India (GOLI) posted revenue/EBITDA/PAT of Rs3.60bn/554mn/359mn in Q4FY20, down 18%/25%/24% yoy and 15%/29%/36% qoq (13%/30%/32% below our estimates), due to a significant Covid-19-led hit on volumes in the second half of March.
- Total reported lube sales volumes plummeted 16% yoy/11% qoq to 25mn ltr (12% miss), with core volumes down 14% yoy. Usual heavy March-end selling activities were disrupted by Covid-19. April was further weak, though volumes started recovering from May.
- Net realization fell 4% qoq to Rs143/ltr, while unit COGS was lower by 3%. Hence, gross margin contracted 5% qoq to Rs71/ltr (up 6% yoy). Unit opex rose 17% yoy/3% qoq to Rs49/ltr on lower volumes. EBITDA/ltr declined 11% yoy/19% qoq to Rs22, a 19% miss.
- With volume outlook fluid now, we build in a 20% fall in FY21 (vs. 7% growth earlier) but assuming FY22 volume growth at 20%. We cut FY21/22E EPS by 37%/26% and TP by 21% to Rs870. GOLI is our SMID pick and we maintain Buy on a Covid-19 recovery story.

Result highlights: Interest cost jumped from average Rs35-40mn to Rs100mn in Q4 due to Rs60mn forex losses. Other Income rose 16% yoy/20% qoq to Rs102mn and ETR was slightly lower at 23%. Depreciation was in line. Employee cost rose 12% yoy, while other expenditure fell 6% yoy/11% qoq. EBITDA margins fell to 15.4% in Q4 vs. ~18% in 9M. For FY20, GOLI's revenue/EBITDA/PAT was down 4%/up 1%/up 14% at Rs16.4/2.87/2.03bn (Rs40.4/sh EPS). PAT was driven by new lower tax rate. EBITDA was largely flat due to a 7% volume decline (110.5mn ltr), offset by 9% EBITDA/ltr growth. Core volumes fell 2% vs. 6-7% for the industry. The board recommended the final dividend of Rs7/sh (total Rs14/sh, 35% payout).

Management guidance: March-end usually sees major schemes and sale activities, but the lockdown impacted volumes this time severely. It was otherwise growing at 10% in all segments, except OEM till Q3FY20. It gained market share by 0.2-0.3%. Agriculture saw volumes from April itself, while infra-industrial, DEO, 2W are seeing an uptick now. 80-85% of distributor markets opened. Maintain 2-3x industry guidance, though estimates pointed to double-digit industry decline in FY21. Lube is a semi essential. Base oil prices saw softness with crude, though weak rupee was an offset. It expect margin retention as things stabilize. It is taking cost optimization measures. Retail outlets increased to 78,000 (~10% yoy). New B2B-OEM tie ups are under works and would be announced. Cash position is healthy.

**Valuation**: Due to the lack of clarity now, estimating FY21 volume is difficult, though FY22 should see material recovery. We also build in a 14%/10% cut in EBITDA/ltr. Reiterate Buy. We value GOLI at 20x FY22E EPS. Key risks are adverse base oil prices-currency, competition, economic slowdown, delay in Covid-19 recovery and technological changes.

Please see our sector model portfolio (Emkay Alpha Portfolio): Oil & Gas (Page 8)

# Financial Snapshot (Standalone)

(Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	17,058	16,435	13,027	15,864	17,787
EBITDA	2,831	2,865	2,162	2,838	3,197
EBITDA Margin (%)	16.6	17.4	16.6	17.9	18.0
APAT	1,778	2,025	1,593	2,180	2,551
EPS (Rs)	35.7	40.4	31.8	43.5	50.9
EPS (% chg)	11.9	13.2	(21.3)	36.8	17.0
ROE (%)	33.7	30.0	19.5	23.1	23.3
P/E (x)	17.6	15.6	19.8	14.5	12.4
EV/EBITDA (x)	11.0	10.4	13.0	9.6	8.1
P/BV (x)	5.3	4.1	3.6	3.1	2.7

Source: Company, Emkay Research

Change in Estimates	
EPS Chg FY21E/FY22E (%)	(37)/(26)
Target Price change (%)	(20.9)
Target Period (Months)	12
Previous Reco	BUY

**EPS Estimates** 

#### **Emkay vs Consensus**

El o Estillatos							
	FY21E	FY22E					
Emkay	31.8	43.5					
Consensus	46.4	53.9					
Mean Consensus TP (	12M)	Rs 842					
Stock Details							
Bloomberg Code		GOLI IN					
Face Value (Rs)		2					
Shares outstanding (m	n)	50					
52 Week H/L		907 / 450					
M Cap (Rs bn/USD bn)	)	32 / 0.41					

Shareholding Pattern Mar '20	
Promoters	72.3%
FIIs	12.0%
DIIs	5.4%
Public and Others	10.3%

12.648

Price Performance										
(%)	1M	3M	6M	12M						
Absolute	12	12	(24)	(30)						
Dol to Nifty	(2)	(6)	(0)	(10)						

# Relative price chart

Daily Avg Volume (nos.)

Daily Avg Turnover (US\$ mn)



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

#### Sabri Hazarika

sabri.hazarika@emkayglobal.com +91 22 6612 1282

# Tanay Gabhawala

tanay.gabhawala@emkayglobal.com +91 22 6612 1336

Exhibit 1: Actual vs. Estimates (Q4FY20)

Rs mn	Actual	Estimates		Varia	tion	Comment	
	Actual	Emkay	Consensus	Emkay	Consensus	Comment	
Total Revenue	3,597	4,153	4,517	-13%	-20%	Due to lower volumes	
Adjusted EBITDA	554	787	792	-30%	-30%	Lower volumes and margins	
EBITDA Margin (%)	15%	19%	18%	-355bps	-213bps		
Adjusted Net Profit	359	525	578	-32%	-38%		

Source: Company, Emkay Research

**Exhibit 2: Detailed quarterly highlights** 

Rs mn	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	% yoy	% qoq	FY19	FY20	% yoy
Sales volume (mn.ltr)	30.0	29.5	27.5	28.4	25.2	-16%	-11%	119.2	110.6	-7%
Automotive^	18.0	18.6	17.6	18.2	15.6	-13%	-14%	71.1	70.0	-2%
Non-automotive <sup>^</sup>	12.0	10.9	9.9	10.2	9.6	-20%	-6%	48.1	40.6	-15%
Core Sales volume (mn.ltr)	29.4	29.5	27.5	28.4	25.2	-14%	-11%	112.9	110.6	-2%
Total revenue	4,362	4,407	4,213	4,219	3,597	-18%	-15%	17,058	16,435	-4%
Net realization (Rs./ltr)	145.4	149.4	153.2	148.5	142.7	-2%	-4%	143.1	148.6	4%
Decrease in stocks	115	(259)	114	(33)	27	-76%		(282)	(150)	
Raw material cost	2,146	2,304	1,861	1,996	1,658	-23%	-17%	8,989	7,820	-13%
Purchases	98	209	162	131	123	25%	-6%	675	625	-7%
COGS	2,358	2,255	2,138	2,094	1,808	-23%	-14%	9,383	8,295	-12%
COGS/ltr (Rs.)	78.6	76.4	77.7	73.7	71.7	-9%	-3%	78.7	75.0	-5%
Gross profit	2,004	2,152	2,075	2,124	1,789	-11%	-16%	7,675	8,140	6%
Gross margin (Rs./ltr)	66.8	72.9	75.5	74.8	71.0	6%	-5%	64.4	73.6	14%
Employee cost	260	266	295	287	291	12%	1%	1,017	1,140	12%
Other expenses	1,001	1,107	1,022	1,061	944	-6%	-11%	3,827	4,135	8%
OPEX	1,262	1,373	1,318	1,349	1,235	-2%	-8%	4,845	5,275	9%
OPEX/Itr (Rs.)	42.1	46.5	47.9	47.5	49.0	17%	3%	40.6	47.7	17%
Total expenditure	3,620	3,628	3,456	3,443	3,043	-16%	-12%	14,227	13,570	-5%
EBITDA	742	779	757	775	554	-25%	-29%	2,831	2,865	1%
EBITDA/ltr (Rs.)	24.7	26.4	27.5	27.3	22.0	-11%	-19%	23.7	25.9	9%
Depreciation	59	80	79	81	87	49%	8%	224	327	46%
EBIT	683	699	678	694	467	-32%	-33%	2,607	2,538	-3%
Interest	26	34	70	44	100	292%	129%	152	248	64%
Other income	88	84	84	85	102	16%	20%	295	355	20%
PBT	746	749	692	736	468	-37%	-36%	2,751	2,645	-4%
Tax expense	270	262	72	177	109	-60%	-38%	973	620	-36%
PAT	476	487	620	559	359	-24%	-36%	1,778	2,025	14%
EPS (Rs)	9.6	9.8	12.4	11.2	7.2	-25%	-36%	35.7	40.5	13%
No. of shares O/S (mn)-FV 5	49.8	49.8	50.1	50.1	50.1	1%	0%	49.8	50.1	1%
EBITDA margin	17%	18%	18%	18%	15%			17%	17%	
NPM	11%	11%	15%	13%	10%			10%	12%	
Effective tax rate	36%	35%	10%	24%	23%			35%	23%	
Reported net debt (ex CM)	(95)	-	(744)	-	(1,750)			(95)	(1,750)	
Inventories	3,388	-	3,235	-	3,283			3,388	3,283	
Sundry debtors	1,507	-	1,904	-	1,870			1,507	1,870	
Creditors	1,959	-	2,086	-	2,585			1,959	2,585	

Source: Company, Emkay Research; ^not reported in results

**Exhibit 3: Changes in assumptions** 

Exhibit 5. Changes in assumptions										
	FY21E				FY22E		FY23E			
	Old	New	% Chg.	Old	New	% Chg.	Introduced			
EBITDA/Itr (Rs.)	28.3	24.4	-14%	29.6	26.7	-10%	27.4			
Growth	3%	-6%	-870bps	5%	9%	460bps	2%			
Sales Volume (mn.ltr)	124	88	-29%	137	106	-22%	117			
Growth	7%	-20%	-2,700bps	10%	20%	1,000bps	10%			

Source: Emkay Research

**Exhibit 4: Changes in estimates** 

		FY21E			FY22E		FY23E
Rs bn	Old	New	% Chg.	Old	New	% Chg.	Introduced
Revenue	19,033	13,027	-32%	21,308	15,864	-26%	17,787
EBITDA	3,515	2,162	-38%	4,052	2,838	-30%	3,197
EBITDA Margins	18%	17%	-187bps	19%	18%	-113bps	18%
PAT	2,528	1,593	-37%	2,953	2,180	-26%	2,551
EPS (Rs)	50.5	31.8	-37%	58.9	43.5	-26%	50.9

Source: Emkay Research

# **Concall highlights**

# Volumes and operations

- GOLI's Q4FY20 volume de-growth was 13.5% yoy. In the last few days of March, major activities happen and schemes are launched generally, but this time it was affected by Covid-19 lockdown, which impacted sales. In major cities, restrictions imposed from 15-16 March vs 23-24 March, when the nationwide lockdown was announced officially.
- FY20 core revenue was down only 1-2% vs. a 6-7% decline of market/industry. Gaining market share in most categories (overall expansion of 0.2-0.3% yoy). Up to December, all categories, except OEM-factory fills, were growing at double digit (10%), though due to the lockdown, for full year FY20, growth was 6%. Up to February 2020, operations were normal. Inst. order adjusted, gross margin improved till December.
- April was a complete shutdown but few essential categories (agri, marine, etc.) started, while May saw a good pick-up and June further better.
- Currently, all depots are operational. April onwards, agriculture started doing better with green shoots of recovery. Mahindra/Swaraj OEM tie-ups helped GOLI.
- 80-85% of distributor markets opened by June (now), whereas 95% of distributors are open. Segment demand opening up are in agri, DEO, infra, industrial and MCO. DEO CV showrooms have also opened.
- Full demand recovery to pre-Covid-19 levels will take time. Lube is a semi-essential so demand will come. There is pent up demand.
- Maintain 2-3x of industry growth guidance. Consultant Kline initially reported a double-digit industry volume decline estimate in FY20 due to Covid-19. But when markets de-grew in the past also, GOLI outperformed.

# Pricing, margins and costing

- Base oil prices saw some downtick (partial) with oil prices with varying degrees among different grades, but now oil is recovering (1-2 months lag pricing to oil). Rupee depreciation would increase costs. There were supply side disruptions in Feb-March from South Korea. Large part of the base oil is imported by independent players as PSU refining capacity is used by OMCs.
- Competitive scenario is affected by the lockdown. It did not take any price action (cut) recently, though schemes keep changing. The benefit of a fall in base oil price was passed on. Expect margin retention as things stabilize.
- Taking cost optimization measures and will try to variabilize opex. 25% of sales revenue is Other Expenses of which OEM royalties is variable. Would try to rationalize A&P spends also (6-7%). Social media exposure enhanced.

# Channel and branding

- The number of retail outlets increased to 78,000 by FY20 end. Confident on strong supply chain and distribution expansion.
- There are number of programs for bazaar market. New B2B-OEM tie ups are under works and would be announced going ahead. The Piaggio deal is for 3W CVs. Also tying up with ecommerce providers for online lube sales.
- Distribution expansion and brand building are key focus areas. It is not looking at low pricing product markets like pump oil, autorickshaw oils etc. Seeking good markets like PM, DEO etc where customers are willing to pay and seek value. Want more people to consider Gulf.

Post recent Brandtrack analysis, Gulf brand is now clear No.2 among all lube brands in India. This is based on awareness level, top of mind recall, brand trial etc. Last 3-4 years, brand equity has improved, which has led to pricing powers. Trying to move up the brand matrix and aspiring for top position. Will be innovative.

#### Results

- Cash position was healthy at Rs1.97bn net. Net OCF improved to Rs2.37bn. Working capital was well managed. Though payables also increased with renegotiations (on payment term extension) with vendors/suppliers, receivables and inventory were also well controlled. After the lockdown, some increase in working capital days was there due to inventory and receivables. Collections picked up in May (at 70% of normal) vs lower in April.
- No inventory loss recorded in Q4/FY20 as M2M difference doesn't arise as the gap between finished lubes and base oil prices is 50%. So cost is always lower vs. NRV.
- Forex loss on interest in Q4FY20 was Rs60mn. It had unrealized portion also. B2C share was 62% vs. 64% in Q3FY20.
- Lube sales volume for FY20 was 110.5mn ltr vs. 119mn ltr in FY19 (which included 6mn ltr of insti order).

# **Others**

- OEM-factory fill volume share is 8-10%. DEO is 40% of which 15% is agri oils. 37-40% of volume mix is CVO, 24-25% PM of which MCO is substantial and PCMO is low.
- Focus went to safety of staff and partners post lockdown. It did CSR in terms of transfer of token amount to mechanics (as they didn't have income). Trade partners were also made part of CSR. It supplied PPE kits and sanitizers. Focused on training also.
- Covid-19 may delay global EV investments and shift. No firm decision is taken on battery capex plans. It is still weighing trade vs. setting a manufacturing unit.
- As per result notes and press release, automotive industry slowdown (OEM, new vehicles), overall weakness in economy, liquidity crunch and Covid-19 in Q4FY20 are reasons behind weaker performance. It launched new products and upgrades during Q4 like Gulf Supreme DUTY ULE (BS VI compliant) and Gulf XHD Supreme Plus (agri). GOLI has restarted both the plants and all warehouses in a phased manner. It doesn't expect carrying amounts of assets to be impacted due to Covid-19.

# Exhibit 5: Valuation

Rs.	FY17	FY18	FY19	FY20E	FY21E	FY22E	FY23E
EPS	23.7	31.9	35.7	40.4	31.8	43.5	50.9
Target Multiple (x)						20.0	
Target Price						870	

Source: Company, Emkay Research

# **Key Financials (Standalone)**

# **Income Statement**

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	17,058	16,435	13,027	15,864	17,787
Expenditure	14,227	13,570	10,864	13,026	14,590
EBITDA	2,831	2,865	2,162	2,838	3,197
Depreciation	224	327	355	368	372
EBIT	2,607	2,538	1,808	2,470	2,825
Other Income	295	355	469	546	642
Interest expenses	152	248	147	102	57
PBT	2,751	2,645	2,130	2,914	3,410
Tax	973	620	537	734	859
Extraordinary Items	0	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	1,778	2,025	1,593	2,180	2,551
Adjusted PAT	1,778	2,025	1,593	2,180	2,551

# **Balance Sheet**

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Equity share capital	100	100	100	100	100
Reserves & surplus	5,768	7,513	8,628	10,045	11,652
Net worth	5,867	7,613	8,728	10,145	11,752
Minority Interest	0	0	0	0	0
Loan Funds	2,831	3,759	2,759	1,759	759
Net deferred tax liability	196	143	100	57	13
Total Liabilities	8,895	11,515	11,587	11,961	12,525
Net block	2,705	2,805	2,880	2,796	2,708
Investment	58	57	58	59	60
Current Assets	8,655	11,597	11,023	11,946	12,935
Cash & bank balance	2,926	5,509	6,198	6,070	6,346
Other Current Assets	507	595	472	574	644
<b>Current liabilities &amp; Provision</b>	2,530	2,951	2,377	2,843	3,182
Net current assets	6,125	8,647	8,646	9,103	9,753
Misc. exp	0	0	0	0	0
Total Assets	8,895	11,515	11,587	11,961	12,525

# **Cash Flow**

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
PBT (Ex-Other income) (NI+Dep)	2,455	2,290	1,661	2,368	2,768
Other Non-Cash items	(39)	57	0	0	0
Chg in working cap	(1,826)	8	646	(628)	(417)
Operating Cashflow	170	2,368	2,270	1,475	1,920
Capital expenditure	(275)	(426)	(426)	(284)	(284)
Free Cash Flow	(105)	1,942	1,844	1,190	1,635
Investments	(2)	1	(1)	(1)	(1)
Other Investing Cash Flow	(237)	244	0	0	0
Investing Cashflow	(219)	174	42	261	357
Equity Capital Raised	0	1	0	0	0
Loans Taken / (Repaid)	350	928	(1,000)	(1,000)	(1,000)
Dividend paid (incl tax)	(653)	(421)	(478)	(763)	(944)
Other Financing Cash Flow	166	(218)	1	1	1
Financing Cashflow	(288)	41	(1,624)	(1,864)	(1,999)
Net chg in cash	(336)	2,583	688	(128)	277
Opening cash position	3,262	2,926	5,509	6,198	6,070
Closing cash position	2,926	5,509	6,198	6,070	6,346

Source: Company, Emkay Research

# **Key Ratios**

Profitability (%)	FY19	FY20	FY21E	FY22E	FY23E
EBITDA Margin	16.6	17.4	16.6	17.9	18.0
EBIT Margin	15.3	15.4	13.9	15.6	15.9
Effective Tax Rate	35.4	23.4	25.2	25.2	25.2
Net Margin	10.4	12.3	12.2	13.7	14.3
ROCE	35.9	28.4	19.7	25.6	28.3
ROE	33.7	30.0	19.5	23.1	23.3
RoIC	53.3	42.9	32.1	44.3	47.3

Per Share Data (Rs)	FY19	FY20	FY21E	FY22E	FY23E
EPS	35.7	40.4	31.8	43.5	50.9
CEPS	40.2	46.9	38.9	50.9	58.3
BVPS	117.8	151.9	174.2	202.5	234.6
DPS	11.5	14.0	9.5	15.2	18.8

Valuations (x)	FY19	FY20	FY21E	FY22E	FY23E
PER	17.6	15.6	19.8	14.5	12.4
P/CEPS	15.7	13.4	16.2	12.4	10.8
P/BV	5.3	4.1	3.6	3.1	2.7
EV / Sales	1.8	1.8	2.2	1.7	1.5
EV / EBITDA	11.0	10.4	13.0	9.6	8.1
Dividend Yield (%)	1.8	2.2	1.5	2.4	3.0

Gearing Ratio (x)	FY19	FY20	FY21E	FY22E	FY23E
Net Debt/ Equity	0.0	(0.2)	(0.4)	(0.4)	(0.5)
Net Debt/EBIDTA	0.0	(0.6)	(1.6)	(1.5)	(1.7)
Working Cap Cycle (days)	68.4	69.7	68.6	69.8	69.9

Growth (%)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	28.0	(3.7)	(20.7)	21.8	12.1
EBITDA	20.1	1.2	(24.5)	31.3	12.6
EBIT	15.7	(2.6)	(28.8)	36.6	14.4
PAT	12.1	13.9	(21.3)	36.8	17.0

Quarterly (Rs mn)	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20
Revenue	4,362	4,407	4,213	4,219	3,597
EBITDA	742	779	757	775	554
EBITDA Margin (%)	17.0	17.7	18.0	18.4	15.4
PAT	476	487	620	559	359
EPS (Rs)	9.5	9.8	12.4	11.2	7.2

Source: Company, Emkay Research

Shareholding Pattern (%)	Mar-19	Jun-19	Sep-19	Dec-19	Mar-20
Promoters	72.7	72.7	72.3	72.3	72.3
FIIs	9.3	10.8	11.9	11.9	12.0
DIIs	5.6	5.3	4.8	5.2	5.4
Public and Others	12.4	11.1	11.0	10.6	10.3


Source: Capitaline

# RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
6-May-20	565	1,100	12m	Buy	Sabri Hazarika
13-Feb-20	791	1,100	12m	Buy	Sabri Hazarika
24-Jan-20	810	1,200	12m	Buy	Sabri Hazarika
4-Dec-19	797	1,200	12m	Buy	Sabri Hazarika
12-Nov-19	848	1,200	12m	Buy	Sabri Hazarika
25-Oct-19	853	1,255	12m	Buy	Sabri Hazarika
23-Sep-19	885	1,255	12m	Buy	Sabri Hazarika
31-Jul-19	766	1,090	12m	Buy	Sabri Hazarika
18-Jun-19	900	1,090	12m	Buy	Sabri Hazarika
10-Jun-19	900	1,150	12m	Buy	Sabri Hazarika
16-May-19	831	1,150	12m	Buy	Sabri Hazarika
14-Feb-19	889	1,150	12m	Buy	Sabri Hazarika
3-Dec-18	762	1,150	12m	Buy	Sabri Hazarika

Source: Company, Emkay Research

# RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

# Emkay Alpha Portfolio - Oil & Gas

EAP sector portfolio



Source: Emkay Research

■ High Conviction/Strong Over Weight ■ High Conviction/Strong Under Weight

Analyst: Sabri Hazarika

**Contact Details** 

sabri.hazarika@emkayglobal.com +91 22 6612 1282

Sector

Oil & Gas

#### Analyst bio

Sabri Hazarika holds an MBA and comes with 11 years of research experience. His team currently covers 12 stocks in the Indian Oil & Gas space.


# Sector portfolio NAV

	Base					Latest
	1-Apr-19	16-Sep-19	18-Dec-19	18-Mar-20	18-May-20	17-Jun-20
EAP - Oil & Gas	100.0	86.7	105.9	66.1	90.3	102.4
BSE200 Neutral Weighted Portfolio (ETF)	100.0	87.3	106.0	66.9	90.2	102.4

<sup>\*</sup>Performance measurement base date 1st April 2019

Source: Emkay Research

#### **NAV** chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): <u>SMID</u>

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

<sup>\*</sup> Not under coverage: Equal Weight

# **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Completed Date: 19 Jun 2020 09:06:03 (SGT) Dissemination Date: 19 Jun 2020 09:07:03 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayqlobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on the sender. Further, this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

# ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

# COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of June 18, 2020
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of June 18, 2020.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the June 18, 2020
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the June 18, 2020

<sup>&</sup>lt;sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>&</sup>lt;sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

# **RESTRICTIONS ON DISTRIBUTION**

TEGITAGE TIGHT	301142011014
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom.
United Kingdom	In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

# Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com